Catalyst Pharmaceuticals Reports Record Financial Results and Business Update for 2024

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) has reported its financial results for the fourth quarter and full year of 2024, marking another year of record growth and strong commercial performance. The company's total revenues for the full year reached $491.7 million, a 23.5% increase year-over-year (YoY), driven by the successful launch of AGAMREE and the sustained organic growth of FIRDAPSE. Catalyst's management team will host a conference call and webcast on February 27, 2025, at 8:30 AM ET to discuss these results and provide a business update.



Catalyst's record 2024 performance is a reflection of the company's successful launch of AGAMREE and its continued outstanding commercial capabilities that fuel the momentum of its existing products. Achieving total revenues for 2024 of $491.7 million demonstrates the strength of Catalyst's scalable business model and the dedication of its teams to patient care. In 2025, the company intends to not only seek to continue successfully growing its revenues from sales of its existing products but also to continue its robust business development efforts, its efforts to protect FIRDAPSE's intellectual property, and its efforts to increase the geographical availability of FIRDAPSE for LEMS patients.



Catalyst's full-year 2024 financial highlights include:

* Total revenues of $491.7 million, a 23.5% YoY increase
* FIRDAPSE full-year 2024 product revenue, net of $306.0 million, an 18.4% YoY increase
* AGAMREE 2024 product revenue, net of $46.0 million, reflecting the strong commercial launch of the product
* FYCOMPA full-year product revenue, net of $137.3 million, despite differences in variable consideration (gross-to-net) in 2024 compared to the 2023 period
* License and other revenue for 2024 of $2.4 million, consisting primarily of a $2.1 million milestone payment

Catalyst's Q4 2024 net product revenue of $141.8 million was fueled by the sustained organic growth of FIRDAPSE and the continued market adoption of AGAMREE. The company's strategic investments to expand its market presence and accelerate growth are expected to drive continued growth momentum in 2025, with full-year total revenues projected to be between $545 million and $565 million.

Catalyst Pharmaceuticals' balance of commercial success, intellectual property protection, and geographical expansion strategies helps mitigate risks and enhance its competitive position in the biotech sector. The company's strong commercial performance, driven by the successful launch of AGAMREE and the sustained organic growth of FIRDAPSE, demonstrates its ability to effectively market and sell its products. Catalyst's focus on protecting FIRDAPSE's intellectual property ensures that it can maintain its competitive advantage and continue to innovate. Expanding the geographical availability of FIRDAPSE for LEMS patients allows Catalyst to tap into new markets and increase its customer base, further solidifying its position as a leader in the biotech sector.

In conclusion, Catalyst Pharmaceuticals' record-breaking financial performance in 2024, driven by the successful launch of AGAMREE and the sustained organic growth of FIRDAPSE, positions the company for continued success in 2025 and beyond. The company's strategic focus on rare diseases and biotech innovations, combined with its balance of commercial success, intellectual property protection, and geographical expansion strategies, helps mitigate risks and enhance its competitive position in the biotech sector. Investors can expect Catalyst to continue growing its revenues from sales of its existing products and pursuing strategic investments to expand its market presence and accelerate growth.